Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin ly2605541 versus insulin glargine

Diabetes Care

Volumn 37, Issue 3, 2014, Pages 659-665

  Bergenstal, Richard M ^a   Rosenstock, Julio ^b   Bastyr III, Edward J ^c   Prince, Melvin J ^c   Qu, Yongming ^c   Jacober, Scott J ^c  

^a INTERNATIONAL DIABETES CENTER   (United States)

^b DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN GLARGINE; INSULIN PEGLISPRO; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLARGINE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN LISPRO; LONG ACTING INSULIN; MACROGOL DERIVATIVE;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD LEVEL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE VARIABILITY; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; METABOLISM; MULTICENTER STUDY; TREATMENT OUTCOME;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84896711004     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2621     Document Type: Article

References (26)

1. Beck RW, Calhoun P, Kollman C. Use of continuous glucose monitoring as an outcome measure in clinical trials. Diabetes Technol Ther 2012;14:877-882
2. Sartore G, Chilelli NC, Burlina S, et al. The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM). Acta Diabetol 2012;49 (Suppl. 1):S153-S160
3. Testa MA, Gill J, Su M, Turner RR, Blonde L, Simonson DC. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial. J Clin Endocrinol Metab 2012;97:3504-3514
4. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937-948
5. Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Tech 2008;2:1094-1100
6. Cox DJ, Kovatchev BP, Julian DM, et al. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab 1994; 79:1659-1662
7. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007;50:2553-2561
8. Monnier L, Wojtusciszyn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011;13:813-818
9. Murata GH, Hoffman RM, Shah JH, Wendel CS, Duckworth WC. A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus: The Diabetes Outcomes in Veterans Study (DOVES). Arch Intern Med 2004;164:1445-1450
10. Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther 2012;14:1008-1012
11. Penckofer S, Quinn L, Byrn M, Ferrans C, Miller M, Strange P. Does glycemic variability impact mood and quality of life? Diabetes Technol Ther 2012;14:303-310
12. Jacober SJ, Rosenstock J, Bergenstal RM, Prince MJ, Qu Y, Beals JM. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycemic control in T1D and T2D (Abstract). Diabetes 2012; 61(Suppl. 1):A262
13. Heise T, Howey DC, Sinha VP, Choi SL,Mace KF. Steady-state pharmacokinetics (PK) and glucodynamics (GD) of the novel, longacting basal insulin LY2605541 in patients with type 2 diabetes mellitus (Abstract). Diabetologia 2012;55(Suppl. 1):S375
14. Sinha VP, Howey DC, Soon DKW, et al. Single-dose pharmacokinetics (PK) and glucodynamics (GD) of the novel, longacting basal insulin LY2605541 in healthy subjects (Abstract). Diabetes 2012;61:A273
15. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147
16. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998;21:1870-1875
17. Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003; 5:817-828
18. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009;11(Suppl. 1): S55-S67
19. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009;11:551-565
20. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011;34:795-800
21. Blevins TC, Bode BW, Garg SK, et al.; AACE Continuous Glucose Monitoring Task Force. Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring. Endocr Pract 2010;16:730-745
22. Chico A, Vidal-Ŕios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003;26:1153-1157
23. Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo-and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther 2003;5:19-26
24. Weber KK, Lohmann T, Busch K, Donati-Hirsch I, Riel R. High frequency of unrecognized hypoglycaemias in patients with type 2 diabetes is discovered by continuous glucose monitoring. Exp Clin Endocrinol Diabetes 2007;115:491-494
25. Zick R, Petersen B, Richter M, Haug C; SAFIR Study Group. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther 2007;9: 483-492
26. Welsh JB, Kaufman FR, Lee SW. Accuracy of the Sof-sensor glucose sensor with the iPro calibration algorithm. J Diabetes Sci Tech 2012;6:475-476